Leveraging a computational platform designed to exploit the full potential of a widely studied pharma target has proved successful in attracting venture investors in the last few years to Structure Therapeutics Inc. The company now is giving the public markets a go, aiming to raise up to $100 million in what marks the first biopharma U.S. IPO filing for 2023. Read More
China Resources Biopharmaceutical Co. Ltd. (CR Biopharm) raised ¥600 million (US$89 million) in a series B round led by China Structural Reform Fund Co. Ltd. Beijing, China-based CR Biopharm plans to use the funds to accelerate the discovery of biological drugs and support the ongoing clinical trials of its candidates, as well as look for in-licensing opportunities. Read More
The accelerated approval by the U.S. FDA of Immunogen Inc.’s landmark antibody-drug conjugate Elahere (mirvetuximab soravtansine-gynx) injected further oomph into the NaPi2b space, where a handful of developers are due to yield important data shortly. In play are such names as Mersana Therapeutics Inc. and Zymeworks Inc., encouraged by historical – if not entirely successful – efforts by giant Roche Holding AG. Read More
Following Therapeutic Goods Administration approval of its first-generation donor-derived microbiome-based therapy, Biomictra, for recurrent Clostridioides difficile infection, Australia’s Biomebank is scaling up to meet increasing global demand for fecal microbiota products and is developing a more scalable second-generation synthetic product. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adaptive Phage, Advaxis, CNS, Midatech, Oramed, Point. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aitia, Alvotech, Arecor, Astrazeneca, Cambrian, Cybin, Fuji, G3, Hikima, Iama, Immunon, Isterian, Nfl, Pheno, Psychogenics, UCB, Zynerba. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Astrazeneca, Biontech, Genentech, Pfizer. Read More
